A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population

Trial Profile

A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ABSORB China
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 28 Jan 2016 According to an Abbott media release, results from this trial were presented at the Transcatheter Cardiovascular Therapeutics conference in October 2015.
    • 12 Oct 2015 Results published in the Journal of the American College of Cardiology, as per Abbott media release.
    • 12 Oct 2015 Results published in Abbott media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top